Clinical trials
Phase 1 Muscular Dystrophies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nationwide Children's Hospital | 3 |
| Cedars-Sinai Medical Center | 2 |
| Edgewise Therapeutics, Inc. | 2 |
| GlaxoSmithKline | 2 |
| Allergy and Asthma Consultants, Wichita, Kansas | 1 |
| Cure Rare Disease, Inc | 1 |
| GAAD Medical Research Institute Inc. | 1 |
| Jerry R. Mendell | 1 |
| Medical University of Bialystok | 1 |
| Neurogen Brain and Spine Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Dystrophies | 21 |
| Muscular Dystrophy, Duchenne | 14 |
| Muscular Diseases | 3 |
| Musculoskeletal Diseases | 3 |
| Nervous System Diseases | 3 |
| Neuromuscular Diseases | 3 |
| Genetic Diseases, Inborn | 2 |
| Muscular Disorders, Atrophic | 2 |
| Myotonic Dystrophy | 2 |
| Cardiomyopathies | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.